PRESS RELEASE published on 02/12/2025 at 07:30, 1 year 1 month ago Inside Information / Other news releases GenSight Biologics reports 5-year efficacy and safety results for LUMEVOQ® gene therapy in REFLECT study with sustained visual improvement and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity REFLECT Study
BRIEF published on 01/23/2025 at 18:50, 1 year 1 month ago GenSight Biologics: Financial Report and Outlook GenSight Biologics Capital Increases LUMEVOQ® Compassionate Access Treasury 2024
PRESS RELEASE published on 01/23/2025 at 18:45, 1 year 1 month ago Inside Information / News release on accounts, results GenSight Biologics reports end-of-year cash position and provides business update, including successful capital increases and ongoing review of LUMEVOQ dossier Business Update Cash Position GenSight Biologics Capital Increases LUMEVOQ Dossier
BRIEF published on 01/15/2025 at 07:35, 1 year 2 months ago GenSight Biologics Reports Long-Term Results for LUMEVOQ® Gene Therapy GenSight Biologics LUMEVOQ® Visual Acuity Leber's Hereditary Optic Neuropathy
PRESS RELEASE published on 01/15/2025 at 07:30, 1 year 2 months ago Inside Information / Other news releases GenSight Biologics announces the publication of 5-year outcomes for patients treated with LUMEVOQ® gene therapy, showing sustained bilateral improvement in visual acuity and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity Safety Profile
BRIEF published on 01/13/2025 at 11:31, 1 year 2 months ago Heights Capital Management exceeds 5% stake in GenSight Biologics Capital Increase Shares And Voting Rights GenSight Biologics Heights Capital Management Capital Participation
BRIEF published on 12/24/2024 at 20:51, 1 year 2 months ago GenSight Biologics Secures €1.5 Million Financing from Existing Investors Investors Warrants Financing Gene Therapy GenSight Biologics
PRESS RELEASE published on 12/24/2024 at 20:46, 1 year 2 months ago Inside Information / Other news releases GenSight Biologics announces a c. €1.5 million financing from existing investors through a Reserved Offering to support gene therapy development for retinal diseases and CNS disorders Financing Gene Therapy GenSight Biologics Retinal Diseases Reserved Offering
BRIEF published on 11/13/2024 at 07:35, 1 year 4 months ago GenSight Biologics Submits LUMEVOQ® Dossier to ANSM Gene Therapy GenSight Biologics Early Access Program Leber Hereditary Optic Neuropathy Regulatory Submission
PRESS RELEASE published on 11/13/2024 at 07:30, 1 year 4 months ago Inside Information / Other news releases GenSight Biologics submits updated LUMEVOQ Dossier to ANSM for early access program restart in France to treat LHON, aiming for first injections in December 2024 GenSight Biologics LHON LUMEVOQ Early Access Program ANSM
Published on 03/16/2026 at 14:00, 47 minutes ago Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression
Published on 03/16/2026 at 13:45, 1 hour 2 minutes ago iFabric Corp Provides Strong 2025 Revenue Estimate and 2026 Outlook
Published on 03/16/2026 at 13:30, 1 hour 17 minutes ago Ondas Completes Acquisition of Rotron Aerospace Ltd., Expanding Long-Range Propulsion Technologies for Advanced Unmanned Systems for Defense
Published on 03/16/2026 at 13:30, 1 hour 17 minutes ago An Asteroid Just Hit Earth - Where Did Everything Land? New Global Challenge Seeks Answers
Published on 03/16/2026 at 13:30, 1 hour 17 minutes ago Tactical Resources Signs Agreement to Acquire the Sierra Blanca Quarry and Tailings Access for the Peak Rare Earth Project
Published on 03/16/2026 at 14:04, 43 minutes ago Sartorius launches next-generation platform to boost efficiency in cell therapy production
Published on 03/16/2026 at 08:30, 6 hours 17 minutes ago CDA - Update on CDA' parks solarization program
Published on 03/13/2026 at 19:50, 2 days 18 hours ago Availability of ENGIE’S 2025 Universal Registration Document
Published on 03/13/2026 at 18:05, 2 days 20 hours ago Availability of the 2025 Universal Registration Document of OPmobility SE
Published on 03/13/2026 at 07:30, 3 days 7 hours ago BIOPHYTIS PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE
Published on 03/12/2026 at 18:00, 3 days 20 hours ago NEW OR RENEWED AGREEMENTS BETWEEN EURAZEO AND CERTAIN FAMILY SHAREHOLDERS
